DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02423824

COGDYS-GLP1

CompletedPhase 3

Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists

Exploring the Neural Substrates of Cognitive Dysfunction With Glucagon-like Peptide-1 Agonists

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

21

actual

Study population

Alzheimer's / cognition, Psychiatric (schizophrenia / bipolar / depression)

Key I/E criterion

—

Primary endpoint

•Executive function

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02423824
Org study ID14-8561-A

Timeline

Milestones

Study first posted2015-04-22estimated
Last update posted2016-05-13estimated
Study start2015-05 (month precision)
Primary completion2016-04actual (month precision)
Study completion2016-05actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Alzheimer's / cognitionPsychiatric (schizophrenia / bipolar / depression)

Eligibility

Who can enroll

Minimum age18 Years
Maximum age45 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Informed consent before study-related activity

2. Individuals between the ages of 18 and 45 who meet DSM-5 criteria for bipolar disorders or depressive disorders

3. Below-average (i.e. 1 standard deviation below norm) performance in the TMTB.

4. Individuals must be receiving guideline concordant pharmacotherapy, in stable doses, without withdrawal or addition of medication in the last month.

Exclusion criteria

1. Diagnosis of possible or probable AD, MCI, or any other dementia

2. History of neurological disorder (ischemic attacks, carotid bruits, or lacunes upon MRI scan), or evidence of neurologic or other physical illness that could produce cognitive deterioration

3. Individuals in a severe mood episode, defined as a Hamilton Depression Rating scale 17- item (HAMD-17) total score of >23 or a Young Mania Rating Scale (YMRS) total score of >20.

4. Actively suicidal or evaluated as being a suicide risk (operationalized as a score of ≥3 on HAMD-17 suicide item and/or by clinical assessment).

5. Substance use disorder within 3 months before screening or a positive baseline toxicology screen.

6. Currently being treated for diabetes, with oral hypoglycemic agents and/or insulin, as these medications affect glucose and insulin levels, as well as the HOMA-IR calculation.

7. Presence of absolute or relative contraindication to liraglutide (e.g. hepatic impairment, renal impairment with CKD stage 3 and above, personal or familial history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2)

8. History of alcoholism; history of pancreatitis or pancreatic cancer

9. Presence of clinically unstable general medical illness.

10. Pregnancy or breastfeeding women.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
1
Other (unclassified)
1

Other clinical outcomes

1 endpoint
Primary/protocol endpoint

Executive function

Time frame:4 weeks

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Resting-state functional network connectivity

Time frame:4 weeks

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.